184 related articles for article (PubMed ID: 23877655)
21. The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity.
Ahn YH; Hong SO; Kim JH; Noh KH; Song KH; Lee YH; Jeon JH; Kim DW; Seo JH; Kim TW
Clin Exp Immunol; 2015 Jul; 181(1):164-78. PubMed ID: 25753156
[TBL] [Abstract][Full Text] [Related]
22. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
[TBL] [Abstract][Full Text] [Related]
23. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
[TBL] [Abstract][Full Text] [Related]
24. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector.
Liu Y; Chiriva-Internati M; Grizzi F; Salati E; Roman JJ; Lim S; Hermonat PL
Cancer Gene Ther; 2001 Dec; 8(12):948-57. PubMed ID: 11781657
[TBL] [Abstract][Full Text] [Related]
25. Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer.
Rahma OE; Herrin VE; Ibrahim RA; Toubaji A; Bernstein S; Dakheel O; Steinberg SM; Abu Eid R; Mkrtichyan M; Berzofsky JA; Khleif SN
J Transl Med; 2014 Dec; 12():353. PubMed ID: 25510844
[TBL] [Abstract][Full Text] [Related]
26. [Research of SOCS1 silent DC vaccine on laryngocarcinoma therapy].
Yuan Y; Wang XF; Zhang Y; Wang JY; Luan N
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Feb; 26(4):169-73. PubMed ID: 22568257
[TBL] [Abstract][Full Text] [Related]
27. Silenced suppressor of cytokine signaling 1 (SOCS1) enhances the maturation and antifungal immunity of dendritic cells in response to Candida albicans in vitro.
Shi D; Li D; Yin Q; Qiu Y; Yan H; Shen Y; Lu G; Liu W
Immunol Res; 2015 Mar; 61(3):206-18. PubMed ID: 25381480
[TBL] [Abstract][Full Text] [Related]
28. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
30. Oral Administration of Poly-Gamma-Glutamic Acid Significantly Enhances the Antitumor Effect of HPV16 E7-Expressing
Kim E; Yang J; Sung MH; Poo H
J Microbiol Biotechnol; 2019 Sep; 29(9):1444-1452. PubMed ID: 31387341
[TBL] [Abstract][Full Text] [Related]
31. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.
Grasso F; Negri DR; Mochi S; Rossi A; Cesolini A; Giovannelli A; Chiantore MV; Leone P; Giorgi C; Cara A
Int J Cancer; 2013 Jan; 132(2):335-44. PubMed ID: 22700466
[TBL] [Abstract][Full Text] [Related]
32. Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70.
Zhou L; Zhu T; Ye X; Yang L; Wang B; Liang X; Lu L; Tsao YP; Chen SL; Li J; Xiao X
Hum Gene Ther; 2010 Jan; 21(1):109-19. PubMed ID: 19715402
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients.
Ferrara A; Nonn M; Sehr P; Schreckenberger C; Pawlita M; Dürst M; Schneider A; Kaufmann AM
J Cancer Res Clin Oncol; 2003 Sep; 129(9):521-30. PubMed ID: 12898233
[TBL] [Abstract][Full Text] [Related]
34. The Antitumor Activity of CAR-T-PD1 Cells Enhanced by HPV16mE7-Pulsed and SOCS1-Silenced DCs in Cervical Cancer Models.
Zheng J; Huang J; Ma W; Yang W; Hu B
Cancer Manag Res; 2021; 13():6045-6053. PubMed ID: 34377023
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of Ad-CRT/E7-mediated antitumor effect by preimmunization with L. lactis expressing HPV-16 E7.
Rangel-Colmenero BR; Gomez-Gutierrez JG; Villatoro-Hernández J; Zavala-Flores LM; Quistián-Martínez D; Rojas-Martínez A; Arce-Mendoza AY; Guzmán-López S; Montes-de-Oca-Luna R; Saucedo-Cárdenas O
Viral Immunol; 2014 Nov; 27(9):463-7. PubMed ID: 25216057
[TBL] [Abstract][Full Text] [Related]
36. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model.
Ahn WS; Bae SM; Kim TY; Kim TG; Lee JM; Namkoong SE; Kim CK; Sin JI
Hum Gene Ther; 2003 Oct; 14(15):1389-99. PubMed ID: 14577920
[TBL] [Abstract][Full Text] [Related]
37. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells.
De Bruijn ML; Schuurhuis DH; Vierboom MP; Vermeulen H; de Cock KA; Ooms ME; Ressing ME; Toebes M; Franken KL; Drijfhout JW; Ottenhoff TH; Offringa R; Melief CJ
Cancer Res; 1998 Feb; 58(4):724-31. PubMed ID: 9485027
[TBL] [Abstract][Full Text] [Related]
38. Modified DCs and MSCs with HPV E7 antigen and small Hsps: Which one is the most potent strategy for eradication of tumors?
Bolhassani A; Shahbazi S; Agi E; Haghighipour N; Hadi A; Asgari F
Mol Immunol; 2019 Apr; 108():102-110. PubMed ID: 30802787
[TBL] [Abstract][Full Text] [Related]
39. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
40. Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments.
Kang TH; Lee JH; Noh KH; Han HD; Shin BC; Choi EY; Peng S; Hung CF; Wu TC; Kim TW
Int J Cancer; 2007 Apr; 120(8):1696-703. PubMed ID: 17230516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
